Levine Cancer Institute

Running trials

• Recruiting

  Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

  NCT07745361· Phase 2· Monte Rosa Therapeutics, Inc· Source

• Recruiting

  Pre-malignant States to Hematologic Malignancies in Firefighters

  NCT06870760· Wake Forest University Health Sciences· Source

• Recruiting

  A Study of ARC-02 in B-cell NHL

  NCT07691606· Phase 1· Taiho Oncology, Inc.· Source

• Recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

  NCT07124078· Phase 2· Incyte Corporation· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

  NCT07291297· Phase 2· Wake Forest University Health Sciences· Source

• Active, not recruiting

  A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

  NCT07194044· Phase 1· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Digoxin Medulloblastoma Study

  NCT06701812· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients

  NCT06958107· Wake Forest University Health Sciences· Source

• Active, not recruiting

  A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

  NCT06888921· Phase 1/2· Compugen Ltd· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

  NCT06517641· Phase 2· Medical College of Wisconsin· Source

• Recruiting

  Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

  NCT06580106· Wake Forest University Health Sciences· Source

• Recruiting

  A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  NCT06615050· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

  NCT06523621· Phase 2· Wake Forest University Health Sciences· Source

• Recruiting

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Wake Forest University Health Sciences· Source

• Recruiting

  Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

  NCT06607406· Wake Forest University Health Sciences· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

  NCT06619561· Phase 2· Deciphera Pharmaceuticals, LLC· Source

• Recruiting

  The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  NCT06377852· Phase 3· American Society of Clinical Oncology· Source

• Recruiting

  A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

  NCT06343805· Phase 1· Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source

• Active, not recruiting

  Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

  NCT06555796· Phase 1· Amgen· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

  NCT06381141· Phase 1· Cullinan Therapeutics Inc.· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Active, not recruiting

  A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

  NCT06577025· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

  NCT06096779· Phase 2· Genentech, Inc.· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

  NCT06027268· Phase 2· Wake Forest University Health Sciences· Source

• Recruiting

  Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

  NCT05997017· Phase 2· Aadi Bioscience, Inc.· Source

• Recruiting

  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Phase 1· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  NCT05828511· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Active, not recruiting

  A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05257083· Phase 3· Stichting European Myeloma Network· Source

• Recruiting

  First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

  NCT06043817· Phase 1/2· Pierre Fabre Medicament· Source

• Recruiting

  A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

  NCT05797805· Phase 1/2· Iterion Therapeutics· Source

• Recruiting

  Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

  NCT05919511· Incyte Corporation· Source

Showing 50 of 115.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer14 recruiting
• Multiple myeloma9 recruiting
• Lung cancer8 recruiting
• Childhood cancers5 recruiting
• Ovarian cancer5 recruiting
• Sarcoma5 recruiting
• Bladder cancer4 recruiting
• Melanoma4 recruiting
• Prostate cancer4 recruiting
• Colorectal cancer3 recruiting
• Head and neck cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Follicular lymphoma2 recruiting
• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• Aplastic anaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting

Closed trials

• Completed

  WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

  NCT06291324· Wake Forest University Health Sciences· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

  NCT05336409· Phase 1· Century Therapeutics, Inc.· Source

• Terminated

  Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

  NCT05027594· Phase 1· Nerviano Medical Sciences· Source

• Terminated

  Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

  NCT05224661· Center for International Blood and Marrow Transplant Research· Source

• Completed

  A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  NCT05347485· Phase 2· Janssen Scientific Affairs, LLC· Source

• Terminated

  Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

  NCT05126433· Phase 2· Jazz Pharmaceuticals· Source

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Pfizer· Source

• Completed

  FT576 in Subjects With Multiple Myeloma

  NCT05182073· Phase 1· Fate Therapeutics· Source

• Terminated

  Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

  NCT04892446· Phase 2· Gilead Sciences· Source

• Completed

  Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

  NCT04796194· Phase 2· Lytix Biopharma AS· Source

• Completed

  Intensive Preventative Dental Program Pilot Study

  NCT07218068· Early phase 1· Wake Forest University Health Sciences· Source

• Completed

  A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

  NCT05022849· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

  NCT04981795· Incyte Corporation· Source

• Completed

  A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation

  NCT05016310· Wake Forest University Health Sciences· Source

• Withdrawn

  Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

  NCT04230031· Phase 2· Wake Forest University Health Sciences· Source

• Completed

  A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

  NCT04699630· Phase 2· SCRI Development Innovations, LLC· Source

• Withdrawn

  Patients Who Receive 131 I-MIBG

  NCT04770831· Wake Forest University Health Sciences· Source

• Completed

  A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

  NCT04398485· Phase 1· Ionis Pharmaceuticals, Inc.· Source

• Terminated

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  NCT04383210· Phase 2· Elevation Oncology· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

  NCT04150965· Phase 1/2· Multiple Myeloma Research Consortium· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Phase 1/2· Bolt Biotherapeutics, Inc.· Source

• Completed

  A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

  NCT03984097· Phase 1· Takeda· Source

• Completed

  Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

  NCT03904134· Center for International Blood and Marrow Transplant Research· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  NCT03869190· Phase 1/2· Hoffmann-La Roche· Source

• Terminated

  RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

  NCT03894215· Phase 2· Agenus Inc.· Source

• Completed

  Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

  NCT03939637· Phase 3· Baylor College of Medicine· Source

• Completed

  Myeloma-Developing Regimens Using Genomics (MyDRUG)

  NCT03732703· Phase 1/2· Multiple Myeloma Research Consortium· Source

• Completed

  Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

  NCT03748186· Phase 1· Sutro Biopharma, Inc.· Source

• Completed

  LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

  NCT03773107· Phase 1/2· Wake Forest University Health Sciences· Source

• Completed

  An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

  NCT03601078· Phase 2· Celgene· Source

• Completed

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

  NCT03456063· Phase 3· Hoffmann-La Roche· Source

• Terminated

  MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

  NCT03461354· Wake Forest University Health Sciences· Source

• Completed

  A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

  NCT03467373· Phase 1· Hoffmann-La Roche· Source

• Completed

  LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

  NCT03361306· Phase 2· Wake Forest University Health Sciences· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Incyte Corporation· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Astellas Pharma Global Development, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Pharmacyclics LLC.· Source

• Completed

  A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  NCT02716116· Phase 1/2· Takeda· Source

• Completed

  Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

  NCT02375555· Phase 2· Dana-Farber Cancer Institute· Source

• Completed

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

  NCT02017717· Phase 3· Bristol-Myers Squibb· Source

• Completed

  The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

  NCT01566695· Phase 3· Celgene· Source

• Completed

  Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

  NCT01421524· Phase 1· Celgene· Source

Showing 50 of 51.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma48 works · 48 trials
• Mantle cell lymphoma11 works · 4 trials
• Myeloproliferative neoplasms11 works · 5 trials
• Chronic lymphocytic leukaemia10 works · 2 trials
• Sickle cell disease9 works · 3 trials
• Aplastic anaemia3 works · 2 trials